POSTMENOPAUZA DAVRIDAGI GORMONAL O‘ZGARISHLAR VA SUT BEZI SARATONI RIVOJLANISH XAVFI (ADABIYOTLAR SHARXI)

Authors

  • Talipov O.A Toshkent Davlat Tibbiyot Universiteti, Toshkent. O’zbekiston, PhD
  • Saloxiddinova M.R Toshkent Davlat Tibbiyot Universiteti, Toshkent. O’zbekiston, magistr
  • Almurodova D.M Toshkent Davlat Tibbiyot Universiteti, Toshkent. O’zbekiston, PhD

Keywords:

postmenopause, breast cancer, aromatase, estrogen receptors, catechol-estrogens, obesity, insulin resistance, literature review.

Abstract

 Sut bezining xavfli o‘smalari ayollar populyatsiyasida o‘lim xavfi yuqori bo‘lgan yetakchi onkologik patologiya hisoblanadi. Sut bezi saratoni (SBS) holatlarining ko’p qismi aynan postmenopauza davriga to‘g‘ri keladi. Ushbu davrda tizimli estrogenlar kamayishiga qaramay, gormonga sezgir estrogen retseptorlai musbat (ER+) o‘smalar ko‘payishi tibbiyotda o‘ziga xos "estrogen paradoksi"ni yuzaga keltiradi.

References

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249.

Arnold, M., Morgan, E., Rumgay, H., Mafra, A., Singh, D., Laversanne, M., ... & Soerjomataram, I. (2022). Current and future burden of breast cancer: Global estimates for 2020 and projections to 2040. The Breast, 66, 15-23.

Henderson, B. E., & Feigelson, H. S. (2000). Hormonal carcinogenesis. Carcinogenesis, 21(3), 427-433.

Clemons, M., & Goss, P. (2001). Estrogen and the risk of breast cancer. New England Journal of Medicine, 344(4), 276-285.

Labrie, F., Luu-The, V., Labrie, C., Belanger, A., Simard, J., Lin, S. X., & Pelletier, G. (2017). Endocrine and intracrine mechanisms of aging and breast cancer. The Journal of Steroid Biochemistry and Molecular Biology, 165, 122-131.

Simpson, E. R., & Brown, K. A. (2019). Obesity and breast cancer: role of inflammation and aromatase. Trends in Molecular Medicine, 25(5), 415-425.

Bulun, S. E., Chen, D., Lu, P., Amin, S., & Zhao, H. (2020). Aromatase and regulatory mechanisms in breast cancer. Journal of the Endocrine Society, 4(11), bvaa134.

Fortner, R. T., Sieri, S., Berrino, F., et al. (2018). Sex hormones and risk of breast cancer in premenopausal and postmenopausal women: Results from the EPIC cohort. International Journal of Cancer, 142(7), 1340-1350.

Endogenous Hormones and Breast Cancer Collaborative Group. (2021). Free and total insulin-like growth factor-I, sex hormone-binding globulin, and breast cancer risk: MESA cohort analysis. Cancer Epidemiology, Biomarkers & Prevention, 30(3), 522-531.

Yager, J. D., & Davidson, N. E. (2006). Estrogen carcinogenesis in breast cancer. New England Journal of Medicine, 354(3), 270-282.

Russo, J., & Russo, I. H. (2006). The role of estrogen and the molecular basis of breast cancer. Endocrine-Related Cancer, 13(3), 705-731.

Musgrove, E. A., Caldon, C. E., Barraclough, J., Alazawi, A., & Sutherland, R. L. (2011). Cyclin D1 and endocrine therapy resistance in breast cancer. Nature Reviews Cancer, 11(8), 558-572.

Cavalieri, E., & Rogan, E. (2016). The molecular etiology of breast cancer and other human cancers: Estrogen DNA-adducts. Molecular Aspects of Medicine, 50, 1-116.

Santen, R. J., Yue, W., & Wang, J. P. (2015). Estrogen production and action in postmenopausal breast cancer: intracrinology and genotoxicity. The Journal of Steroid Biochemistry and Molecular Biology, 145, 134-139.

Neuhouser, M. L., Aragaki, A. K., Prentice, R. L., et al. (2015). Overweight, obesity, and postmenopausal breast cancer risk: The Women's Health Initiative randomized clinical trials. JAMA Oncology, 1(5), 611-621.

Howe, L. R., Subbaramaiah, K., Hudis, C. A., & Dannenberg, A. J. (2013). Molecular pathways: adipose inflammation as a mediator of breast cancer risk. Clinical Cancer Research, 19(24), 6677-6683.

Iyengar, N. M., Gucalp, A., Dannenberg, A. J., & Hudis, C. A. (2016). Obesity and cancer mechanisms: tumor microenvironment and systemic factors. Annual Review of Medicine, 67, 383-399.

Brown, K. A. (2021). Metabolic pathways linking obesity and breast cancer. Nature Reviews Endocrinology, 17(11), 637-649.

Pollak, M. (2012). The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nature Reviews Cancer, 12(3), 159-169.

Rossouw, J. E., Anderson, G. L., Prentice, R. L., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 288(3), 321-333.

Collaborative Group on Hormonal Factors in Breast Cancer. (2019). Type and timing of menopausal hormone therapy and breast cancer risk: global collaborative re-analysis of individual participant data. The Lancet, 394(10204), 1159-1168.

Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 310(13), 1353-1368.

Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the WHI randomized clinical trials. JAMA, 324(4), 369-380.

Santen, R. J., Allred, D. C., Sherman, S. P., et al. (2014). High intratumoral levels of estrogens in postmenopausal breast cancer: mechanisms and clinical significance. The Journal of Clinical Endocrinology & Metabolism, 99(11), 3953-3962.

Yue, W., Wang, J. P., Li, Y., & Santen, R. J. (2010). Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms. International Journal of Cancer, 127(8), 1748-1757.

Downloads

Published

2026-05-30

How to Cite

Talipov O.A, Saloxiddinova M.R, & Almurodova D.M. (2026). POSTMENOPAUZA DAVRIDAGI GORMONAL O‘ZGARISHLAR VA SUT BEZI SARATONI RIVOJLANISH XAVFI (ADABIYOTLAR SHARXI). IQRO , 21(2), 1765–1776. Retrieved from https://www.wordlyknowledge.uz/index.php/iqro/article/view/7599